Jpmorgan Chase & CO Brooklyn Immuno Therapeutics, Inc. Put Options Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding BTX

# of Institutions
1
Shares Held
1.21M
Call Options Held
0
Put Options Held
0
View Full List

About Brooklyn ImmunoTherapeutics, Inc.

BTX Quotes by TradingView
  • Ticker BTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,825,700
  • Description
  • Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...
More about BTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email